SecBot SecBot
Biotech Drug Report Generated Oct 31, 2026

trevogrumab

REGN·REGENERON PHARMACEUTICALS, INC.
NEUTRAL
Drug Impact Rating3/10
Trial phase
Phase 2
Time to market
Trevogrumab is in Phase 2 development with no Phase 3 trial or regulatory filing announced. If a Phase 3 program begins in 2027, potential approval would likely be several years away, assuming positive results.
Why 3/10
No hard dated binary catalyst (PDUFA, pivotal readout, or AdComm) is scheduled in the next ~12 months. The next milestone is a planned Phase 2 trial in older adults with obesity, but no start date has been announced. Trevogrumab is a Phase 2 asset at a large, diversified biotech where it represents a small fraction of overall value.
Actionable Insight NEUTRAL

The next catalyst for trevogrumab is Regeneron's planned Phase 2 trial in older adults with obesity and decreased muscle mass/strength, but no start date has been announced. Investors should watch for trial initiation and any partnership or licensing activity in the muscle-preservation space, as well as competitive developments from Eli Lilly's bimagrumab (Phase 3) and Scholar Rock's apitegromab. Trevogrumab is unlikely to drive material share-price moves for REGN in the next 12 months given the lack of a hard dated binary catalyst and the drug's small weight within Regeneron's diversified pipeline.

Price Chart

Loading chart...

Executive Summary

Trevogrumab (REGN1033) is Regeneron's investigational anti-myostatin monoclonal antibody being developed to preserve muscle mass during GLP-1 agonist-induced weight loss. The Phase 2 COURAGE trial (NCT06299098) met its endpoints, showing trevogrumab 75mg cut lean mass loss by roughly 42% versus semaglutide alone at 52 weeks, with thigh muscle preservation up to 71.8% on MRI. Results were presented at EASD in October 2026 and published in The Lancet. Regeneron plans a follow-up Phase 2 trial in older adults with obesity and low muscle mass, but no Phase 3 trial or regulatory filing has been announced. For a large-cap biotech like Regeneron (market cap ~$93B, many approved blockbusters), trevogrumab is an early-stage pipeline asset with no near-term binary catalyst.

How It Works

Trevogrumab is a lab-made antibody that blocks myostatin (also called GDF8), a protein the body naturally uses to limit muscle growth. By neutralizing myostatin, the drug allows the body to hold onto or build muscle, even during the calorie deficit caused by weight-loss drugs like semaglutide (Wegovy).

Trial Status

The Phase 2 COURAGE trial (NCT06299098) has completed its primary analyses. The 52-week results were presented at the European Association for the Study of Diabetes (EASD) Annual Meeting on October 1, 2026, and are in press with The Lancet. The trial enrolled 1,005 patients with obesity and tested trevogrumab at various doses (25mg, 75mg, 200mg, 400mg) in combination with semaglutide 2.4mg, with and without garetosmab (anti-activin A). Regeneron plans to initiate a new Phase 2 trial in older adults with obesity and decreased muscle mass and/or strength.

The Two-Sided Case

▲ Bull Case4
Phase 2 COURAGE data showed trevogrumab preserved 42-71% of muscle normally lost on semaglutide, a clinically meaningful result in a large and growing GLP-1 market where muscle preservation is a key concern
The data were published in The Lancet and presented at EASD, signaling academic credibility and regulatory interest
Regeneron's VelocImmune platform gives it deep antibody expertise, and the company has the financial resources (Q3 2026 revenue of $5.1B) to advance the program without external funding
The muscle-preservation space is still early, and trevogrumab's selective myostatin blockade may offer a differentiated safety profile versus broader ActRII blockers like bimagrumab
▼ Bear Case4
Trevogrumab is still in Phase 2 with no Phase 3 trial or regulatory filing announced; the path to approval is long and uncertain
The myostatin inhibitor field has a history of failures: earlier candidates (MYO-029, domagrozumab, LY2495655) failed in sarcopenia, and Roche recently discontinued obesity development of its myostatin program
Competition is intensifying: Eli Lilly's bimagrumab is already in Phase 3 with tirzepatide, and Scholar Rock's apitegromab has Phase 2 data with tirzepatide, putting trevogrumab behind key rivals
For Regeneron, a $93B market-cap company with multiple blockbuster products (Dupixent, Eylea, Libtayo), trevogrumab is a small, early-stage pipeline asset unlikely to move the stock meaningfully for years

Upcoming Catalysts

  • Initiation of a Phase 2 trial in older adults with obesity and decreased muscle mass/strength (date not yet announced)
  • Any potential partnership or licensing deals for muscle-preservation assets
  • Competitive readouts from Eli Lilly's bimagrumab (Phase 3) and Scholar Rock's apitegromab

Source Filing

The SecBot filing or press-release report that triggered this drug report:

REGENERON PHARMACEUTICALS, INC. 8-K REGN ·Originating report

Sources · 10

Hover a chip for the title
1 investor.regeneron.com2 en.wikipedia.org3 clinicaltrials.gov4 biomednexus.com5 medicaldaily.com6 investor.regeneron.com7 markets.businessinsider.com8 regeneron.com9 allsci.com10 myostatininhibitorshub.com